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ABSTRACT 
Haemonchus contortus is an important parasitic nematode, both economically and 
pathologically. The emergence of widespread drug resistance requires new drug or 
vaccine targets to be identified . The requirement of aerobic organisms to control 
damage caused by reactive oxygen species and, the increased necessity of parasites to 
overcome the host immune response, has led to the investigation of antioxidant 
systems as potential targets. This work examines the thioredoxin antioxidant system in 
H. contortus, specifically the thioredoxin reductase and peroxiredoxin enzymes, to 
characterise their activity and determine if they are potential targets for parasite 
control. 
H. contortus contains two TrxRs, a cytoplasmic enzyme HcTrxRl with a selenocysteine 
in the active site, similar to the mammalian TrxR, and a mitochondrial enzyme HcTrxR2 
with a nematode unique active site. HcTrxRl showed broad activity with thioredoxins 
from E. coli, sheep, and H. contortus while HcTrxR2 had high activity with only the 
mitochondrial H. contortus thioredoxin 1. Importantly, HcTrxRl was found to be more 
sensitive to the black tea inhibitor theaflavin than the selenocysteine containing 
mammalian TrxR, demonstrating the differences in the enzymes susceptibilities to 
inhibitors. To determine the function of the TrxR enzymes in nematodes, knockout 
(KO) strains of Caenorhabditis elegans were examined. TrxRl -/-KO worms were more 
sensitive to free radical attack and also to the anthelmintic ivermectin; while TrxR2 -/-
KO eggs were highly sensitive to sodium hypochlorite. This demonstrates that 
inhibition of these enzymes would sensitise the nematodes to the host's immune 
attack. 
H. contortus contains two peroxiredoxins, the mitochondrial HcPrxl and the 
cytoplasmic HcPrx2. The activity of both peroxiredoxins was specific for the 
thioredoxin system; however, both peroxiredoxins were also able to be regenerated by 
the glutathione system when coupled to the nematode specific H. contortus 
thioredoxin 5. Both enzymes were stable to high concentrations of hydrogen peroxide 
xi 
which demonstrates different functions to their mammalian counterparts. A specific 
inhibitor of these peroxiredoxins was also identified which has minimal mammalian 
cytotoxicity. HcPrxl was found to be involved in drug resistance while HcPrx2 was 
found to be secreted and highly immunogenic. Analysis of homologous genes in C. 
elegans showed that both peroxiredoxin KO worms were sensitive to free radical 
attack; however, only the cytoplasmic CePrx2 KOC. elegans were sensitive to external 
oxidants. 
Overall, this work adds to the knowledge of H. contortus biology and identifies the 
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